Loading quotes...
Forecast
The analysts' average price target is €41.67 (-7.81%). The median is €42.16 (-6.73%).
| Buy |
12 |
| Hold |
18 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
QIAGEN: one-year return of 4.55% on a €1,000 investment
If QIAGEN shares had been purchased for €1,000 on 29 Oct 2025, investors would now hold 23.182 shares worth €1,045.51, corresponding to a performance of 4.55 percent. According to the calculation, market capitalization most recently stood at about €9.30 billion. Stock splits and dividends were not taken into account in the calculation. » More on finanzen.net
Barclays downgrades QIAGEN to equal weight and cuts target to $53
Barclays lowers its price target for QIAGEN from $55 to $53 and downgrades the stock from "Overweight" to "Equal Weight." Analyst Luke Sergott welcomes the planned takeover by EQT and notes that the $55 bid is very close to his previous target. The QIAGEN share posted slight gains in XETRA trading and is up about 10.4% year-to-date in 2026. » More on finanzen.net
JPMorgan downgrades Qiagen to 'Neutral' and sets price target at EQT takeover offer
JPMorgan lowers its rating for Qiagen from "Overweight" to "Neutral" and cuts the price target to $52, roughly in line with the takeover offer from private equity firm EQT. Qiagen shares closed in New York at $50. » More on finanzen.net
QIAGEN: €100 investment ten years ago rose by 55.8%
A €100 investment in QIAGEN ten years ago would have resulted in 3.639 shares and would have been worth about €155.81 at a price of €42.82 on 21 October 2026. That corresponds to an increase of 55.81%. Stock splits and dividends are not included in the calculation; market capitalization was most recently about €8.97 billion. » More on finanzen.net
Crown NL Bidco offers QIAGEN €46.50 per share in voluntary takeover offer
Crown NL Bidco B.V., controlled by EQT XI with co-investors ADIA and CPP Investments, has announced a voluntary public takeover offer for all ordinary shares of QIAGEN at €46.50 per share. QIAGEN’s management board and supervisory board have entered into a business combination agreement and recommend shareholders accept the offer; the transaction is subject to conditions including a minimum acceptance threshold of 50%, approval of certain resolutions at an extraordinary general meeting, merger and investment regulatory clearances, and other conditions. Post-closing measures are planned that could lead to acquisition of the entire business and the delisting of QIAGEN from the Frankfurt Stock Exchange and the NYSE; closing is currently expected in mid-2027. » More on finanzen.net
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 483.69M | 6.58% |
| Gross profit | 312.53M | 10.72% |
| Net profit | 93.28M | 15.82% |
| EBITDA | 172.94M | 4.66% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €9.33B |
Number of shares | 206.5M |
52-week high/low | €52.71 - €29.66 |
| Dividends | No |
Beta | 0.56 |
P/E ratio | 26.65 |
PEG ratio | -49.83 |
P/B ratio | 2.95 |
P/S ratio | 4.84 |
Company profile
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
| Name | QIAGEN |
| CEO | Jon Pratt |
| Headquarters | Venlo,
li Netherlands |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| IPO | 06/28/1996 |
| Employees | 5,400 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NYSE | QGEN |
XETRA | QIA.DE |
Düsseldorf | QIA.DU |
Frankfurt | QIA.F |
Hamburg | QIA.HM |
London | 0RLT.L |
München | QIA.MU |
SIX | QGEN.SW |
Wien | QGEN.VI |
Milan | 1QGEN.MI |